[go: up one dir, main page]

WO2003066869A8 - Lmt tumor suppressor gene - Google Patents

Lmt tumor suppressor gene

Info

Publication number
WO2003066869A8
WO2003066869A8 PCT/AU2003/000126 AU0300126W WO03066869A8 WO 2003066869 A8 WO2003066869 A8 WO 2003066869A8 AU 0300126 W AU0300126 W AU 0300126W WO 03066869 A8 WO03066869 A8 WO 03066869A8
Authority
WO
WIPO (PCT)
Prior art keywords
tumor suppressor
suppressor gene
present
gene
expression product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2003/000126
Other languages
French (fr)
Other versions
WO2003066869A1 (en
Inventor
Wendy Dianne Cook
Benjamin John Mccaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Original Assignee
Walter and Eliza Hall Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter and Eliza Hall Institute of Medical Research filed Critical Walter and Eliza Hall Institute of Medical Research
Priority to AU2003202315A priority Critical patent/AU2003202315A1/en
Priority to US10/512,477 priority patent/US20050172424A1/en
Publication of WO2003066869A1 publication Critical patent/WO2003066869A1/en
Publication of WO2003066869A8 publication Critical patent/WO2003066869A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Footwear And Its Accessory, Manufacturing Method And Apparatuses (AREA)

Abstract

The present invention relates generally to the field of cancer therapy and cancer diagnostics and to agents useful therefor. More particularly, the present invention provides a novel tumor suppressor gene, an expression product including a polypeptide or protein encoded thereby and nucleic acid probes and primers and peptide fragments characteristic of the tumor suppressor gene or its expression product or mutants or derivatives thereof. The present invention further provides molecules generated through combinatorial chemistry or rational chemical synthesis or identified following screening of chemical libraries or natural sources which augment or otherwise facilitate the activity or function of the tumor suppressor gene or its expression product and in particular in cells which carry a deletion or other mutation including a gene silencing event in one or both alleles of the tumor suppressor gene. The present invention provides diagnostic agents to detect the presence or absence of the tumor suppressor gene or the presence or absence of an expressible tumor suppressor gene or the presence or absence of an expression product of the tumor suppressor gene useful in determining the likelihood of development of a tumor in a vertebrate animal such as mammal and in particular a human. The present invention further provides genetically modified animals carrying cells in which one or both alleles of the tumor suppressor gene are deleted or mutated or where expression of the gene is otherwise silenced.
PCT/AU2003/000126 2002-02-07 2003-02-07 Lmt tumor suppressor gene Ceased WO2003066869A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003202315A AU2003202315A1 (en) 2002-02-07 2003-02-07 Lmt tumor suppressor gene
US10/512,477 US20050172424A1 (en) 2002-02-07 2003-04-30 Lmt turmor suppressor gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPS0371 2002-02-07
AUPS0371A AUPS037102A0 (en) 2002-02-07 2002-02-07 A novel gene

Publications (2)

Publication Number Publication Date
WO2003066869A1 WO2003066869A1 (en) 2003-08-14
WO2003066869A8 true WO2003066869A8 (en) 2004-02-12

Family

ID=3833972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2003/000126 Ceased WO2003066869A1 (en) 2002-02-07 2003-02-07 Lmt tumor suppressor gene

Country Status (3)

Country Link
US (1) US20050172424A1 (en)
AU (1) AUPS037102A0 (en)
WO (1) WO2003066869A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090031582A1 (en) * 2007-07-30 2009-02-05 Anyi Lu Shoe with sock lining and elastic collar
CN105779572B (en) * 2014-12-22 2020-07-07 深圳华大基因研究院 Chip and method for capturing target sequence of tumor susceptibility gene and mutation detection method

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US757816A (en) * 1903-12-29 1904-04-19 Gustavus Krieger Ankle-supporting shoe.
US991036A (en) * 1910-12-13 1911-05-02 Wolf Spiegelman Shoe.
US1717432A (en) * 1928-07-12 1929-06-18 Michael Brite Ankle and arch support for children's shoes
US3590411A (en) * 1968-12-26 1971-07-06 Usm Corp Stiffening processes
US4706316A (en) * 1985-11-27 1987-11-17 Giancarlo Tanzi Method for producing footwear
CA1277135C (en) * 1986-07-21 1990-12-04 Pierre Charles Lepine Adjustable inner sole for footwear
US5152082A (en) * 1991-12-16 1992-10-06 Culpepper Thomas C Shoe and ankle support therefor
US5392532A (en) * 1993-10-18 1995-02-28 R. G. Barry Corporation Slipper having an insole attached to a peripheral outsole wall
US6079128A (en) * 1993-11-30 2000-06-27 Bauer Nike Hockey Inc. Skate boot construction with integral plastic insert
US6041524A (en) * 1998-10-05 2000-03-28 Jeffrey S. Brooks, Inc. Footwear having recessed heel cup
US6519877B2 (en) * 2001-01-12 2003-02-18 K-2 Corporation Snowboard boot with removable upper support

Also Published As

Publication number Publication date
WO2003066869A1 (en) 2003-08-14
US20050172424A1 (en) 2005-08-11
AUPS037102A0 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
Qiu et al. MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets
Dheilly et al. Cathepsin S regulates antigen processing and T cell activity in non-Hodgkin lymphoma
Chopp et al. An integrated epigenomic and transcriptomic map of mouse and human αβ T cell development
US20230203485A1 (en) Methods for modulating mhc-i expression and immunotherapy uses thereof
Marcaurelle et al. Chemical synthesis of lymphotactin: a glycosylated chemokine with a C‐terminal mucin‐like domain
Seim et al. Whole-genome sequence of the metastatic PC3 and LNCaP human prostate cancer cell lines
Chavez et al. Comparative genomics provides new insights into the remarkable adaptations of the African wild dog (Lycaon pictus)
Zou et al. Molecular cloning and characterization of a rabbit eIF2C protein
Lobb et al. Novel function discovery through sequence and structural data mining
Noonan et al. A calmodulin binding site in the tuberous sclerosis 2 gene product is essential for regulation of transcription events and is altered by mutations linked to tuberous sclerosis and lymphangioleiomyomatosis
IL302497A (en) Factors that bind antigenic peptides with modifications and their use
Okubo et al. Monitoring cell physiology by expression profiles and discovering cell type-specific genes by compiled expression profiles
WO2003066869A8 (en) Lmt tumor suppressor gene
Billmyre et al. Saturation transposon mutagenesis enables genome-wide identification of genes required for growth and fluconazole resistance in the human fungal pathogen Cryptococcus neoformans
AU2021286282B2 (en) Chromosome conformation markers of prostate cancer and lymphoma
EP3098231A1 (en) Methods for analyzing methylated cpg islands and gc rich regions
Lou et al. Structural evolution of trypsinogen gene redundancy confers risk for pancreas diseases
Yang et al. Identification and annotation of bovine granzyme genes reveals a novel granzyme encoded within the trypsin-like locus
CA2303327A1 (en) A method for determining the in vivo function of dna coding sequences
Staal et al. Chimeric and mutant CARD9 constructs enable analyses of conserved and diverged autoinhibition mechanisms in the CARD‐CC protein family
Aslam et al. Structural analysis of a missense mutation (Val414Phe) in the catalytic core domain of the factor XIIIA subunit
KR20240124908A (en) How to analyze a sample for cancer-specific immune cells
Laaser et al. Huge splicing frequency in human Y chromosomal UTY gene
Shi et al. TCGADEPMAP–Mapping Translational Dependencies and Synthetic Lethalities within The Cancer Genome Atlas
Zeng et al. A Chinese patient with Rothmund–Thomson syndrome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

WPC Withdrawal of priority claims after completion of the technical preparations for international publication

Ref country code: WO

WWE Wipo information: entry into national phase

Ref document number: 10512477

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP